Moberg Pharma AB (MOB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Moberg Pharma AB (MOB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8015
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged nails, Fast relief of pain and itch, Waterproof liquid bandage, minor skin irritations, diaper rash, skin irritation and rash and dry feet and cracked heels in one step. The company works in collaboration to develop Oral mucositis for the treatment of pain in the oral cavity. It offers licencing in and licencing out services. The company markets its products in Europe, South America, Africa, the Middle East and others. Moberg Pharma is headquartered in Stockholm, Sweden.

Moberg Pharma AB (MOB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Moberg Pharma Acquires DermoPlast from Prestige 13
Moberg Pharma Acquires PediaCare Brands from Strides Pharma for USD5.6 Million 15
Moberg Pharma Acquires Three US OTC Brands from Prestige Brands for USD40 Million 16
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 18
Moberg Pharma Acquires Bupivacaine From Oracain 19
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 20
Partnerships 21
Moberg Pharma Enters into Agreement with Colep 21
Moberg Extends Distribution Agreement with Menarini for Emtrix 22
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 23
Moberg Pharma Extends Distribution Agreement With Menarini 24
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 25
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 26
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 27
Moberg Derma Enters Into Co-Marketing Agreement With Ana Darou For Emtrix 28
Licensing Agreements 29
Cipher Pharma Enters into Licensing Agreement with Moberg Pharma 29
Cadila Pharma Enters into Licensing Agreement with Moberg Pharma 30
Equity Offering 31
Moberg Pharma to Raise USD16 Million in Private Placement of Shares 31
Moberg Pharma Raises USD8.6 Million in Private Placement of Shares 32
Moberg Pharma Completes Rights Offering Of Shares For US$5 Million 34
Debt Offering 35
Moberg Pharma Raises USD32.8 million in Public Offering of Bonds 35
Asset Transactions 36
Randob Labs Acquires Balmex from Moberg Pharma for USD4.2 Million 36
Strides Shasun Acquires Jointflex, Fergon and Vanquish Brands from Moberg Pharma for USD10 Million 37
Acquisition 38
Altaris Capital Sells Minority Stake in Moberg Pharma 38
Moberg Derma Completes Acquisition Of Alterna From Altaris Capital Partners For US$25 Million 39
Moberg Pharma AB – Key Competitors 41
Moberg Pharma AB – Key Employees 42
Moberg Pharma AB – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Financial Announcements 44
Aug 07, 2018: Moberg Pharma interim report January – June 2018 44
May 08, 2018: Moberg Pharma Interim report January – March 2018 46
Feb 13, 2018: Moberg Pharma Year-end Report 2017 48
Nov 13, 2017: Moberg Pharma interim report January – September 2017 50
Aug 08, 2017: Moberg Pharma: interim report January- June 2017 51
May 09, 2017: Moberg Pharma interim report January – March 2017 53
Feb 14, 2017: Moberg Pharma Year-end report 2016 54
Corporate Communications 56
Aug 13, 2018: Moberg Pharma appoints new chief medical officer 56
Apr 19, 2018: Moberg Pharma Announces Resignation Of Kjell Rensfeldt As VP Research and Development 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Moberg Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Moberg Pharma Acquires DermoPlast from Prestige 13
Moberg Pharma Acquires PediaCare Brands from Strides Pharma for USD5.6 Million 15
Moberg Pharma Acquires Three US OTC Brands from Prestige Brands for USD40 Million 16
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 18
Moberg Pharma Acquires Bupivacaine From Oracain 19
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 20
Moberg Pharma Enters into Agreement with Colep 21
Moberg Extends Distribution Agreement with Menarini for Emtrix 22
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 23
Moberg Pharma Extends Distribution Agreement With Menarini 24
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 25
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 26
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 27
Moberg Derma Enters Into Co-Marketing Agreement With Ana Darou For Emtrix 28
Cipher Pharma Enters into Licensing Agreement with Moberg Pharma 29
Cadila Pharma Enters into Licensing Agreement with Moberg Pharma 30
Moberg Pharma to Raise USD16 Million in Private Placement of Shares 31
Moberg Pharma Raises USD8.6 Million in Private Placement of Shares 32
Moberg Pharma Completes Rights Offering Of Shares For US$5 Million 34
Moberg Pharma Raises USD32.8 million in Public Offering of Bonds 35
Randob Labs Acquires Balmex from Moberg Pharma for USD4.2 Million 36
Strides Shasun Acquires Jointflex, Fergon and Vanquish Brands from Moberg Pharma for USD10 Million 37
Altaris Capital Sells Minority Stake in Moberg Pharma 38
Moberg Derma Completes Acquisition Of Alterna From Altaris Capital Partners For US$25 Million 39
Moberg Pharma AB, Key Competitors 41
Moberg Pharma AB, Key Employees 42
Moberg Pharma AB, Subsidiaries 43

List of Figures
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Moberg Pharma AB (MOB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Habib Metropolitan Bank Limited:企業の戦略・SWOT・財務分析
    Habib Metropolitan Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Habib Metropolitan Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Taragenyx Ltd:企業の製品パイプライン分析2018
    Summary Taragenyx Ltd (Taragenyx) is a medical technology company that provides regenerative medicine technology, medical and biological engineering solutions. The company offers restorative implant solutions generation, burdensome operations, and medical, orthopaedic, dental implantation solutions, …
  • SACI Falabella:企業の戦略・SWOT・財務情報
    SACI Falabella - Strategy, SWOT and Corporate Finance Report Summary SACI Falabella - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • National Reinsurance Corporation Of The Philippines
    National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report Summary National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …
  • Constellation Software Inc (CSU):企業の財務・戦略的SWOT分析
    Constellation Software Inc (CSU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Parexel International Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Parexel International Corp (Parexel) is a biopharmaceutical outsourcing service company which focuses on providing various services for managing the biopharmaceutical product lifecycle and for the development and commercialization of new medical therapies. It offers a comprehensive range of …
  • Mitsubishi UFJ Financial Group Inc:企業のM&A・事業提携・投資動向
    Mitsubishi UFJ Financial Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitsubishi UFJ Financial Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • Prologis Inc (PLD):企業の財務・戦略的SWOT分析
    Prologis Inc (PLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Culture Landmark Investment Limited:戦略・SWOT・企業財務分析
    Culture Landmark Investment Limited - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Ferrovial, S.A. (FER):企業の財務・戦略的SWOT分析
    Ferrovial, S.A. (FER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Cenveo, Inc.:企業の戦略的SWOT分析
    Cenveo, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Toleranzia AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Toleranzia AB (Toleranzia) is a drug developer that utilizes immune system’s intrinsic power to treat autoimmune diseases. The company offers products and technologies including Re-Tolerogen for the treatment of autoimmune diseases. Its Re-Tolerogen platform technology is a fusion protein fo …
  • E.ON SE (EOAN)-石油・ガス分野:企業M&A・提携分析
    Summary E.ON SE (E.ON), formerly E.ON AG, is an energy company that generates electricity, produces, stores, transports, and supplies gas and conducts trading, carbon sourcing, and electricity and gas distribution. It generates power from diverse fuel sources including wind, hydro, nuclear, coal, na …
  • United Food Holdings Limited:戦略・SWOT・企業財務分析
    United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • China Resources Enterprise Ltd:企業の戦略的SWOT分析
    China Resources Enterprise Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Benchmark Electronics Inc (BHE):企業の財務・戦略的SWOT分析
    Benchmark Electronics Inc (BHE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Municipal Energy Agency of Nebraska:企業の発電所・SWOT分析2018
    Municipal Energy Agency of Nebraska - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Anek Lines SA:企業の戦略・SWOT・財務情報
    Anek Lines SA - Strategy, SWOT and Corporate Finance Report Summary Anek Lines SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Robert Half International Inc. (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Congenica Ltd-医療機器分野:企業M&A・提携分析
    Summary Congenica Ltd (Congenica) is a biotechnology company that offers research and experimental development on biotechnology. The company’s technology SAPIENTIA, is used to personalize patient care through accurate diagnoses, support clinical trials, and drug development. It offers services such …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆